| Dr Michael Popov, | |
|
2040 W Charleston Blvd, Ste 202a, Las Vegas, NV 89102-2227 | |
| (702) 671-5127 | |
| Not Available |
| Full Name | Dr Michael Popov |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 9 Years |
| Location | 2040 W Charleston Blvd, Las Vegas, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518351097 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | DO2507 (Nevada) | Primary |
| Entity Name | Alliance Mental Health Specialists Suba Park Cheng Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275988107 PECOS PAC ID: 1153616693 Enrollment ID: O20160823003042 |
News Archive
Results of recent surveillance conducted by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe indicate that the annual number of newly diagnosed HIV infections in Europe reached an all-time high in 2014.
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.
A team of scientists led by Associate Professor Zeng Qi from A*STAR's Institute of Molecular and Cell Biology have discovered a new biomarker which will help physicians predict how well cancer patients respond to cancer drugs. Having the means to identify patients who are most likely to benefit from currently available cancer drugs not only reduces substantially the healthcare cost for the patient, it could mean saving precious lives by getting the right drugs to the right patient at the onset of the treatment.
This post in the Center for Global Health Policy's "Science Speaks" blog examines a report by the PEPFAR Scientific Advisory Board (SAB) that offers six recommended treatment and prevention research priorities to U.S. Global AIDS Ambassador Eric Goosby and the Office of the Global AIDS Coordinator (OGAC) to guide future PEPFAR programs.
...and may largely reward those with higher performance at baseline, according to a study in the October 12 issue of JAMA: The Journal of the American Medical Association.
› Verified 2 days ago
| Entity Name | Anywhere Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316460850 PECOS PAC ID: 4183996317 Enrollment ID: O20170822003489 |
News Archive
Results of recent surveillance conducted by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe indicate that the annual number of newly diagnosed HIV infections in Europe reached an all-time high in 2014.
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.
A team of scientists led by Associate Professor Zeng Qi from A*STAR's Institute of Molecular and Cell Biology have discovered a new biomarker which will help physicians predict how well cancer patients respond to cancer drugs. Having the means to identify patients who are most likely to benefit from currently available cancer drugs not only reduces substantially the healthcare cost for the patient, it could mean saving precious lives by getting the right drugs to the right patient at the onset of the treatment.
This post in the Center for Global Health Policy's "Science Speaks" blog examines a report by the PEPFAR Scientific Advisory Board (SAB) that offers six recommended treatment and prevention research priorities to U.S. Global AIDS Ambassador Eric Goosby and the Office of the Global AIDS Coordinator (OGAC) to guide future PEPFAR programs.
...and may largely reward those with higher performance at baseline, according to a study in the October 12 issue of JAMA: The Journal of the American Medical Association.
› Verified 2 days ago
| Entity Name | Medtrans Behavioral Nevada Casal Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245781160 PECOS PAC ID: 7810259165 Enrollment ID: O20180326001159 |
News Archive
Results of recent surveillance conducted by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe indicate that the annual number of newly diagnosed HIV infections in Europe reached an all-time high in 2014.
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.
A team of scientists led by Associate Professor Zeng Qi from A*STAR's Institute of Molecular and Cell Biology have discovered a new biomarker which will help physicians predict how well cancer patients respond to cancer drugs. Having the means to identify patients who are most likely to benefit from currently available cancer drugs not only reduces substantially the healthcare cost for the patient, it could mean saving precious lives by getting the right drugs to the right patient at the onset of the treatment.
This post in the Center for Global Health Policy's "Science Speaks" blog examines a report by the PEPFAR Scientific Advisory Board (SAB) that offers six recommended treatment and prevention research priorities to U.S. Global AIDS Ambassador Eric Goosby and the Office of the Global AIDS Coordinator (OGAC) to guide future PEPFAR programs.
...and may largely reward those with higher performance at baseline, according to a study in the October 12 issue of JAMA: The Journal of the American Medical Association.
› Verified 2 days ago
| Entity Name | Medtrans |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871915892 PECOS PAC ID: 9739437815 Enrollment ID: O20180806002709 |
News Archive
Results of recent surveillance conducted by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe indicate that the annual number of newly diagnosed HIV infections in Europe reached an all-time high in 2014.
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.
A team of scientists led by Associate Professor Zeng Qi from A*STAR's Institute of Molecular and Cell Biology have discovered a new biomarker which will help physicians predict how well cancer patients respond to cancer drugs. Having the means to identify patients who are most likely to benefit from currently available cancer drugs not only reduces substantially the healthcare cost for the patient, it could mean saving precious lives by getting the right drugs to the right patient at the onset of the treatment.
This post in the Center for Global Health Policy's "Science Speaks" blog examines a report by the PEPFAR Scientific Advisory Board (SAB) that offers six recommended treatment and prevention research priorities to U.S. Global AIDS Ambassador Eric Goosby and the Office of the Global AIDS Coordinator (OGAC) to guide future PEPFAR programs.
...and may largely reward those with higher performance at baseline, according to a study in the October 12 issue of JAMA: The Journal of the American Medical Association.
› Verified 2 days ago
| Entity Name | Medtrans Medical Nevada Casal Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750846549 PECOS PAC ID: 1850632365 Enrollment ID: O20190410002272 |
News Archive
Results of recent surveillance conducted by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe indicate that the annual number of newly diagnosed HIV infections in Europe reached an all-time high in 2014.
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.
A team of scientists led by Associate Professor Zeng Qi from A*STAR's Institute of Molecular and Cell Biology have discovered a new biomarker which will help physicians predict how well cancer patients respond to cancer drugs. Having the means to identify patients who are most likely to benefit from currently available cancer drugs not only reduces substantially the healthcare cost for the patient, it could mean saving precious lives by getting the right drugs to the right patient at the onset of the treatment.
This post in the Center for Global Health Policy's "Science Speaks" blog examines a report by the PEPFAR Scientific Advisory Board (SAB) that offers six recommended treatment and prevention research priorities to U.S. Global AIDS Ambassador Eric Goosby and the Office of the Global AIDS Coordinator (OGAC) to guide future PEPFAR programs.
...and may largely reward those with higher performance at baseline, according to a study in the October 12 issue of JAMA: The Journal of the American Medical Association.
› Verified 2 days ago
| Entity Name | Bauza Neuropsychiatry Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912596685 PECOS PAC ID: 7618370040 Enrollment ID: O20210722003696 |
News Archive
Results of recent surveillance conducted by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe indicate that the annual number of newly diagnosed HIV infections in Europe reached an all-time high in 2014.
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.
A team of scientists led by Associate Professor Zeng Qi from A*STAR's Institute of Molecular and Cell Biology have discovered a new biomarker which will help physicians predict how well cancer patients respond to cancer drugs. Having the means to identify patients who are most likely to benefit from currently available cancer drugs not only reduces substantially the healthcare cost for the patient, it could mean saving precious lives by getting the right drugs to the right patient at the onset of the treatment.
This post in the Center for Global Health Policy's "Science Speaks" blog examines a report by the PEPFAR Scientific Advisory Board (SAB) that offers six recommended treatment and prevention research priorities to U.S. Global AIDS Ambassador Eric Goosby and the Office of the Global AIDS Coordinator (OGAC) to guide future PEPFAR programs.
...and may largely reward those with higher performance at baseline, according to a study in the October 12 issue of JAMA: The Journal of the American Medical Association.
› Verified 2 days ago
| Entity Name | Success Tms Of Nevada Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104597202 PECOS PAC ID: 0941691349 Enrollment ID: O20211220000205 |
News Archive
Results of recent surveillance conducted by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe indicate that the annual number of newly diagnosed HIV infections in Europe reached an all-time high in 2014.
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.
A team of scientists led by Associate Professor Zeng Qi from A*STAR's Institute of Molecular and Cell Biology have discovered a new biomarker which will help physicians predict how well cancer patients respond to cancer drugs. Having the means to identify patients who are most likely to benefit from currently available cancer drugs not only reduces substantially the healthcare cost for the patient, it could mean saving precious lives by getting the right drugs to the right patient at the onset of the treatment.
This post in the Center for Global Health Policy's "Science Speaks" blog examines a report by the PEPFAR Scientific Advisory Board (SAB) that offers six recommended treatment and prevention research priorities to U.S. Global AIDS Ambassador Eric Goosby and the Office of the Global AIDS Coordinator (OGAC) to guide future PEPFAR programs.
...and may largely reward those with higher performance at baseline, according to a study in the October 12 issue of JAMA: The Journal of the American Medical Association.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Popov, 2040 W Charleston Blvd, Ste 202a, Las Vegas, NV 89102-2227 Ph: (702) 671-5127 | Dr Michael Popov, 2040 W Charleston Blvd, Ste 202a, Las Vegas, NV 89102-2227 Ph: (702) 671-5127 |
News Archive
Results of recent surveillance conducted by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe indicate that the annual number of newly diagnosed HIV infections in Europe reached an all-time high in 2014.
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.
A team of scientists led by Associate Professor Zeng Qi from A*STAR's Institute of Molecular and Cell Biology have discovered a new biomarker which will help physicians predict how well cancer patients respond to cancer drugs. Having the means to identify patients who are most likely to benefit from currently available cancer drugs not only reduces substantially the healthcare cost for the patient, it could mean saving precious lives by getting the right drugs to the right patient at the onset of the treatment.
This post in the Center for Global Health Policy's "Science Speaks" blog examines a report by the PEPFAR Scientific Advisory Board (SAB) that offers six recommended treatment and prevention research priorities to U.S. Global AIDS Ambassador Eric Goosby and the Office of the Global AIDS Coordinator (OGAC) to guide future PEPFAR programs.
...and may largely reward those with higher performance at baseline, according to a study in the October 12 issue of JAMA: The Journal of the American Medical Association.
› Verified 2 days ago
Dr. Ejine Okoroafor, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 5440 W Sahara Ave, Suite 202, Las Vegas, NV 89146 Phone: 914-426-7774 | |
Dr. Garet Jefferson Zaugg, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2020 Wellness Way Ste 300, Las Vegas, NV 89106 Phone: 702-432-2233 Fax: 702-800-5456 | |
Dr. Muhammed A Hyder, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2465 E Twain Ave, Las Vegas, NV 89121 Phone: 702-789-6201 Fax: 304-522-0686 | |
Dr. Krista Linn Pinard, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3016 W Charleston Blvd Ste 150, Las Vegas, NV 89102 Phone: 702-790-2701 | |
Gobinder S. Chopra, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 6410 Medical Center St Ste A100, Las Vegas, NV 89148 Phone: 702-796-8500 Fax: 702-796-8502 | |
Eden Santiago Lee, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3014 W Charleston Blvd Ste 130, Las Vegas, NV 89102 Phone: 702-671-6475 Fax: 702-671-6440 | |
John Reitano, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 501 S Rancho Dr, Ste I62, Las Vegas, NV 89106 Phone: 702-897-7250 Fax: 702-706-4838 |